Orchid Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 1,597.6 million compared to INR 1,613.77 million a year ago. Revenue was INR 1,686.91 million compared to INR 1,637.42 million a year ago. Net income was INR 75.87 million compared to net loss of INR 138.63 million a year ago. Basic earnings per share from continuing operations was INR 1.86 compared to basic loss per share from continuing operations of INR 2.59 a year ago. Diluted earnings per share from continuing operations was INR 1.86 compared to diluted loss per share from continuing operations of INR 2.59 a year ago. Basic earnings per share was INR 1.86 compared to basic loss per share of INR 3.4 a year ago. Diluted earnings per share was INR 1.86 compared to diluted loss per share of INR 3.4 a year ago.
For the nine months, sales was INR 4,559.98 million compared to INR 3,814.25 million a year ago. Revenue was INR 4,736.99 million compared to INR 3,886.81 million a year ago. Net loss was INR 128.21 million compared to net income of INR 46.35 million a year ago. Basic loss per share from continuing operations was INR 3.14 compared to INR 13.66 a year ago. Diluted loss per share from continuing operations was INR 3.14 compared to INR 13.66 a year ago. Basic loss per share was INR 3.14 compared to basic earnings per share of INR 1.14 a year ago. Diluted loss per share was INR 3.14 compared to diluted earnings per share of INR 1.14 a year ago.